Search results

The purpose of this paper is to describe and summarize the recent emergence of NPS onto the drug market. To show the international and national responses, legal and guidance. To indicate some of the challenges NPS present to jurisdictions. To indicate some of the challenges NPS present to treatment agencies. To outline what is known about prevalence and effects.

A narrative account of the substances becoming known and the response made by jurisdictions.

The use and effects of NPS are slowly becoming known and exchanged between jurisdictions and treatment agencies. The user group appears to differ from the “traditional” substance users groups with which agencies are familiar. The use of the internet is a characteristic of this new market and user group.

New substances are constantly being identified. Previous treatment approaches may not be fully relevant to NPS. The new area of cognition enhancement is being gradually realized.

Treatment agencies need to develop new approaches, both to treat the effects of NPS use and to attract NPS users, who do not identify as “drug users”.

A new user group appears to be emerging. Cognition enhancement is a feature of NPS composition and use/attraction.

An attempt to summarize existing understanding of NPS use and marketing and to predict future trends and needs.

Past research argues that identity-linking messages must use established descriptors of the social group (i.e. prototypical identity appeals) to be effective. The authors show that less established descriptors (i.e. identity-linking messages low in prototypicality) can be optimal for an important customer segment, namely, for those that affectively identify with the social group. This is because of the distinct self-motives underlying the cognitive and affective social identity dimensions.

A pilot and two experimental studies were conducted, using gender and nationality as the target identities.

Consumers feel more hopeful and have higher purchase intention for products advertised using identity depictions that fit with their predominant (uncertainty-reduction or self-enhancement) self-motive. Consumers predominantly high in affective/cognitive social identity prefer identity-linking messages that are low/high in prototypicality. An abstract mindset reverses these effects by encouraging a similarity focus.

Future work should identify potential boundary conditions of the findings. Further, all studies use ascribed social groups. Future work should explore whether consumers relate differently to different social group, such as achieved groups, non-human groups or aspirational groups.

Adverts using established descriptors of a brand’s target social group may no longer fit the brand’s positioning. Understanding when and when not to use less established group descriptors to market brands is important for practitioners.

To the best of the authors’ knowledge, this is the first research to explore the conditions under which priming consumers’ identity using less/more established (i.e. low/high in prototypicality) descriptors has a beneficial, or detrimental, effect on consumers’ purchase intention. In understanding these effects, the authors draw on consumers’ self-motives underlying cognitive and affective identification, a distinction not yet made in the identity-linking communications literature. The authors also explore the mediating role of hope – a central motivating emotion – in identity marketing.

This chapter takes the ‘wakefulness promoting’ drug modafinil as an exemplarity case in the sociology of pharmaceutical enhancement. The chapter draws on empirical data collected through 25 interviews with prospective users of modafinil, focusing on two of the ways in which prospective users of modafinil imagined how the drug might be used in their specific social domains: the use of modafinil as a safety tool in the workplace and its use as a study aid by university students. The data presented in this chapter suggests that although a therapy-enhancement dichotomy is a useful heuristic; it could also be limiting to uphold as it may direct attention away from other ways in which uses for new technologies can be positioned, negotiated, realised and resisted by (potential) users in the context of their daily lives.

European studies have shown lower prevalence rates of prescription stimulant use for cognitive enhancement, especially among student populations, compared to North America. This difference requires more cross-country research of the various factors involved. To find out whether other parts of the globe are witnessing similar increases in extra-medical stimulant use, and how this might relate to cognitive enhancement, requires empirical study of local contexts. This paper aims to argue that the academic and public discussion on cognitive enhancement should consider the specific country context of drug policy and research and rethink which drugs are included under the term cognitive enhancement drugs.

This paper offers a general review and a sociological country comparison between the Netherlands and Finland, focusing not only on prescription stimulants used to treat attention deficit hyperactivity disorder but also illicit amphetamines among young adults and methylphenidate use among Dutch and Finnish participants of the Global Drug Survey. This paper emphasises sociocultural perspectives and the importance of context in cognitive enhancement in general as the line between therapeutic and enhancement use can often be blurred. Data is drawn from global, European and national sources, including the International Narcotics Control Board, European Monitoring Centre for Drugs and Drug Addiction and Global Drug Survey.

There are hardly any national empirical studies done on cognitive enhancement drug use in Finland. On the other hand, there have been studies in the Netherlands showcasing that the use of prescription stimulants and other drugs for enhancement purposes is something that is happening among young people, albeit yet in a relatively small scale. Illicit and licit stimulant use and drug policy action in relation to cognitive enhancement drugs in the two countries varies, emphasising the importance of country context.

Given that cross-country research is scarce, this general review provides one of the first glimpses into cognitive enhancement drug use by comparing the country context and research in Finland, where the phenomenon has not been studied, with the Netherlands, where the topic has received more research and public attention. Further research areas are suggested.

This chapter examines representations of gender in online modafinil markets. While gender has often been absent from scholarship on online drug markets, our analysis demonstrates the ubiquity of gender in representations of modafinil users and sellers. The analysis draws on visual images, blogs, and marketing emails relating to three websites selling modafinil, discussed pseudonymously. We describe the range of ways that notions of gender are represented in advertising. Although women represent around 40% of that buying modafinil online, websites and communications tended not to feature women. Although sexist stereotypes of women were rarely present (in contrast to direct-to-consumer pharmaceutical advertising), the ways that modafinil was imagined tended to focus narrowly on corporate spheres of work and productivity. We contrast this narrow imaginary with female journalists’ own accounts of using modafinil to manage illness and enhance creativity. Thus, we conclude that the ways that modafinil has been imagined reflects working assumptions as to who is considered the ‘normal’ participant in online modafinil markets.

Late life depression is often associated with a poor response to antidepressants; therefore an alternative strategy for therapy is required. Although several studies have reported that phosphatidylserine (PS) may be effective for late life depression and that omega-3 fatty acids DHA and EPA have also proven beneficial for many higher mental functions, including depression, no concrete conclusion has been reached. This study was performed to clarify the effect of PS and omega-3 fatty acid-containing supplement for late life depression by not only clinical evaluation but also salivary cortisol levels. Eighteen elderly subjects with major depression were selected for the study. In all, insufficient improvement had been obtained by antidepressant therapy for at least 6 months. The exclusion criteria from prior brain magnetic resonance images (MRI) included the presence of structural MRI findings compatible with stroke or other gross brain lesions or malformations, but not white matter hypersensitivities. They took a supplement containing PS 100 mg, DHA 119 mg and EPA 70 mg three times a day for 12 weeks. The effects of the supplement were assessed using the 17-item Hamilton depression scale (HAMD17) and the basal levels and circadian rhythm of salivary cortisol. The study adopted them as indices because: salivary cortisol levels are high in patients with depression, their circadian rhythm related to salivary cortisol is often irregular, and these symptoms are alleviated as depression improves. The mean HAM-D17 in all subjects taking the supplement was significantly improved after 12 weeks of taking the supplement. These subjects were divided into 10 non-responders and 8 responders. The basal levels and circadian rhythm of salivary cortisol were normalized in the responders while not in non-responders. PS and omega-3 fatty acids, or other elements of the supplement, may be effective for late life depression, associated with the correction of basal levels and circadian rhythm of salivary cortisol.

The dementias are important disorders of ageing which result in cognitive and functional decline, behaviour change, increasing dependency and premature death. Alzheimer's disease and other dementias are at least as prevalent in older people with learning disabilities as in the general population. In addition, people with Down's syndrome have high rates of early onset Alzheimer's disease. Assessment of dementia in people with learning disabilities is confounded by pre‐existing cognitive and functional impairments and high rates of comorbid disorders. This paper discusses assessment of dementia in people with learning disabilities from a clinical perspective, with reference to the current evidence base.

Considering that many unanswered questions remain regarding the antecedents to entrepreneurial intentions, the purpose of this study is to develop insights from existing theories in entrepreneurship frameworks and apply these in the social entrepreneurship context. Consequently the study examines to what extant beliefs and cognitions shape social entrepreneurial intentions.

Hypotheses were statistically tested using multiple regression analyses based on survey data (n = 156) from individuals in South Africa.

Results support the hypotheses where entrepreneurial alertness significantly explained social entrepreneurial intentions, while self-efficacy showed a positive mediating effect in this relationship.

Policymakers encouraging social entrepreneurship should not only focus on external support factors such as financial support but also deliberately develop interventions by focusing on beliefs and cognitions, which the study has identified as important predictors of social entrepreneurship intentions.

By introducing previously unrelated individual-level factors to social entrepreneurship, closer empirical links are created between these factors in this study.

The claim that super intelligent machines constitute a major existential risk was recently defended in Nick Bostrom’s book Superintelligence and forms the basis of the sub-discipline AI risk. The purpose of this paper is to critically assess the philosophical assumptions that are of importance to the argument that AI could pose an existential risk and if so, the character of that risk.

This paper distinguishes between “intelligence” or the cognitive capacity of an individual and “techne”, a more general ability to solve problems using, for example, technological artifacts. While human intelligence has not changed much over historical time, human techne has improved considerably. Moreover, the fact that human techne has more variance across individuals than human intelligence suggests that if machine techne were to surpass human techne, the transition is likely going to be prolonged rather than explosive.

Some constraints for the intelligence explosion scenario are presented that imply that AI could be controlled by human organizations.

If true, this argument suggests that efforts should focus on devising strategies to control AI rather strategies that assume that such control is impossible.

The biomedical paradigm enjoys growing importance in our society. Biomedicine (e.g., Genetics) seems to occupy the position once held by religion and politics. In this context, every trivial problem of daily life is thought to require an appropriate remedy, and perfect health becomes a paramount value, especially within the upper class.

Medicalization is not only promoted by doctors. Today, other engines of medicalization are also available. These include pharmaceutical companies through marketing, advertising, and disease mongering; active consumers who seek a pharmacological solution – a magic bullet – to solve non-organic problems; technology, because highly sensitive diagnostic tools can now detect potential abnormalities even in very low quantities; and the culture of risk, which is connected to the evolution of diagnostic tools, because it is now always possible to be at risk of something.

The parts of life today considered pathological or quasi-pathological are ever increasing shyness, sadness, imperfect blood pressure, or glucose levels. Progressing editions of the Diagnostic and Statistical Manual (DSM) – the text from which diagnoses of mental illnesses are made – reveal a growing number of syndromes. These “diseases” are diagnosed on the grounds of certain symptoms and the number of weeks they last (quantification). Smartphones, with their tremendous capacity for data collection, contribute to a growth in self-diagnoses. For example, invited to log our every moment of sadness through a “trustworthy” avatar from our app (gamification), we can easily make too much of normal moments of discomfort, immediately seeing them – with a simple computation – transformed into something pathological in need of a cure.